BiotechTube

TNO155 + TNO155 in combination with EGF816 (nazartinib)

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)

Conditions

Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma

Trial Timeline

May 26, 2017 → Jul 4, 2025

NCT ID
NCT03114319

About TNO155 + TNO155 in combination with EGF816 (nazartinib)

TNO155 + TNO155 in combination with EGF816 (nazartinib) is a phase 1 stage product being developed by Novartis for Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC). The current trial status is terminated. This product is registered under clinical trial identifier NCT03114319. Target conditions include Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC).

What happened to similar drugs?

16 of 20 similar drugs in Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC) were approved

Approved (16) Terminated (1) Active (4)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅letrozoleJiangsu Hengrui MedicineApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅FulvestrantAstraZenecaApproved
✅Zoladex and CasodexAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03114319Phase 1Terminated

Competing Products

20 competing products in Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21